Ligand Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Ligand Pharmaceuticals has a total shareholder equity of $700.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $787.2M and $86.3M respectively. Ligand Pharmaceuticals's EBIT is $9.8M making its interest coverage ratio -1.4. It has cash and short-term investments of $170.3M.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | -1.4x |
Cash | US$170.31m |
Equity | US$700.91m |
Total liabilities | US$86.30m |
Total assets | US$787.22m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: LGDN's short term assets ($237.4M) exceed its short term liabilities ($16.8M).
Long Term Liabilities: LGDN's short term assets ($237.4M) exceed its long term liabilities ($69.5M).
Debt to Equity History and Analysis
Debt Level: LGDN is debt free.
Reducing Debt: LGDN has no debt compared to 5 years ago when its debt to equity ratio was 113.4%.
Debt Coverage: LGDN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: LGDN has no debt, therefore coverage of interest payments is not a concern.